Penn Study Shows Link Between Immune System Suppression and Blood Vessel Formation in Tumors


July 14, 2011

Penn Medicine News

PHILADELPHIA - Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might. Now, research from the Perelman School of Medicine at the University of Pennsylvania might help to explain the modest responses. The discovery, published in the July 14 issue of Nature, suggests novel treatment combinations that could boost the power of therapies based on slowing blood vessel growth (angiogenesis).

The Penn investigators, led by George Coukos, MD, PhD, Celso-Ramon Garcia Professor of Reproductive Biology, found that ovarian cancer cells grown under low oxygen conditions – which promote blood vessel formation – secrete chemical signals that suppress the patient's immune system, preventing it from killing off the abnormal cancer cells.

"For the first time, we are realizing that the two programs – angiogenesis and immune suppression – are co-regulated and the two programs are mediated by the same cell types," Coukos says. "This creates new therapeutic opportunities, since the study reveals that in order to effectively suppress angiogenesis, one should also suppress a type of immune cell, called regulatory T cells.Thus, commonly used anti-angiogenesis therapies should be combined with therapeutic maneuvers that eliminate regulatory T cells."

Following hints that there might be cross-talk between the two systems, first author Andrea Facciabene, PhD, research assistant professor of Obstetrics and Gynecology, and colleagues grew ovarian cancer cells under normal oxygen conditions or low oxygen (hypoxic) conditions. When the team looked for differences in the proteins called chemokines secreted under the two growth conditions, they found that one signaling molecule, CCL28, was more abundant in low oxygen cultures. CCL28 was also commonly expressed in hypoxic areas of tumors in animal models.

The Penn investigators found that CCL28 recruited regulatory T cells (called T-regs) in experimental situations. Because T-regs suppress local immune responses, including immune cells that kill tumor cells, the researchers hypothesized that CCL28 signaling could induce immune tolerance. In fact, when they looked at tumors grown in animal models, they found that tumors engineered to express CCL28 grew significantly faster than tumors lacking CCL28 expression.

Together the data suggest that hypoxic conditions suppress the immune reaction through T regulatory cells while promoting blood vessel formation. Therefore, to get the most out of anti-angiogenesis drugs, clinicians might need to combine them with drugs that block T-regs.

"The tools to eliminate T-regs effectively are not presently available in the clinic, but the field is definitely advancing, with several candidate strategies currently being tested," Coukos said.

"The other implication of this study is that if anti-angiogenesis therapy induces tumor hypoxia, that could create a rebound increase in regulatory T cells," he continued. "That rebound could account for some of the resistance that is commonly seen in the clinic after anti-angiogenesis therapy is instituted."

Co-authors on the study include Xiaohui Peng, Klara Balint, Ian S. Hagemann, Andrea Barchetti, Li-Ping Wang, Phyllis A. Gimotty, Priti Lal, and Lin Zhang, all from Penn, and C. Blake Gilks of the University of British Columbia, Vancouver.

The study was funded through grants from the National Cancer Institute and the Ovarian Cancer Research Fund.

Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin, have slowed cancer growth in some patients. However, they have not produced the dramatic responses researchers initially thought they might. Now, research from Penn might help to explain the modest responses. The discovery suggests novel treatment combinations that could boost the power of therapies based on slowing blood vessel growth.

Contact:
Karen Kreeger
Karen.kreeger@uphs.upenn.edu
215-349-5658

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4 billion enterprise.

Penn's Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools and among the top 10 schools for primary care. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $507.6 million awarded in the 2010 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania – recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital – the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2010, Penn Medicine provided $788 million to benefit our community.